含铂一线治疗老年晚期非小细胞肺癌:MILES-3与MILES-4联合分析
该研究联合分析MILES-3和MILES-4两项III期试验,评估在老年晚期非小细胞肺癌患者一线单药化疗基础上加用顺铂的疗效。
要点
- 老年晚期NSCLC一线加用顺铂未显著延长总生存。
- 加用顺铂显著改善无进展生存和客观缓解率。
- 加用顺铂增加严重血液学毒性、乏力及厌食。
核心结论
- 在老年晚期非小细胞肺癌患者中,一线单药化疗加用顺铂未显著延长总生存,也未改善生活质量全局健康状况评分。
研究设计与样本
- 联合分析两项平行III期试验MILES-3和MILES-4,纳入年龄>70岁、ECOG体能状态0-1的晚期NSCLC患者。
- 患者随机接受吉西他滨或培美曲塞,不加或加用顺铂;共531例(MILES-3 299例,MILES-4 232例),不加顺铂268例,加顺铂263例。
- 试验因入组缓慢提前终止,联合数据库按意向治疗分析,并按试验、组织学类型、非铂配伍药物、分期、体能状态、性别、年龄和研究中心规模校正。
主要发现
- 中位随访2年,记录384例死亡和448例无进展生存事件。
- 加用顺铂组严重血液学毒性、乏力及厌食显著增多。
临床怎么用
- 对于老年晚期NSCLC患者,一线单药化疗加用顺铂虽改善无进展生存和缓解率,但未延长总生存且毒性增加,需个体化权衡获益与风险。
局限性
- 两项试验均因入组缓慢提前终止,实际样本量未达预设事件数。
- 联合分析按意向治疗进行,但试验提前终止可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To test the efficacy of adding cisplatin to first-line treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC) within a combined analysis of two parallel phase III trials, MILES-3 and MILES-4. Patients and Methods Patients with advanced NSCLC who were older than age 70 years with Eastern Cooperative Oncology Group performance status 0 to 1 were randomly assigned to gemcitabine or pemetrexed, without or with cisplatin. In each trial, 382 events were required to detect a hazard ratio (HR) of death of 0.75, with 80% power and two-tailed α of .05. Trials were closed prematurely because of slow accrual, but the joint database allowed us to analyze the efficacy of cisplatin on the basis of intention-to-treat and adjusted by trial, histotype, non-platinum companion drug, stage, performance status, sex, age, and size of the study center. Results From March 2011 to August 2016, 531 patients (MILES-3, 299; MILES-4, 232) were assigned to gemcitabine or pemetrexed without (n = 268) or with cisplatin (n = 263). Median age was 75 years, 79% were male, and 70% had nonsquamous histology. At a median 2-year follow-up, 384 deaths and 448 progression-free survival events were recorded. Overall survival was not significantly prolonged with cisplatin (HR, 0.86; 95% CI, 0.70 to 1.05; P = .14) and global health status score of quality of life was not improved, whereas progression-free survival (HR, 0.76; 95% CI, 0.63 to 0.92; P = .005) and objective response rate (15.5% v 8.5%; P = .02) were significantly better. Significantly more severe hematologic toxicity, fatigue, and anorexia were found with cisplatin. Conclusion The addition of cisplatin to single-agent chemotherapy does not significantly prolong overall survival, and it does not improve global health status score of quality of life in elderly patients with advanced NSCLC.
引用
- Gridelli C, Morabito A, Cavanna L, et al. Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. J Clin Oncol. 2018. PMID: 30028656. doi:10.1200/JCO.2017.76.8390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。